864OPembrolizumab for high-risk (HR) non–muscle invasive...

Annals of Oncology 2018 / 10 Vol. 29; Iss. suppl_8

864OPembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

de Wit, R, Kulkarni, G S, Uchio, E, Singer, E A, Krieger, L, Grivas, P, Bajorin, D, Seo, H K, Mourey, L, Kamat, A, Nishiyama, H, Kapadia, E, Nam, K, Frenkl, T, Balar, A
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy283.073
Date:
October, 2018
File:
PDF, 79 KB
english, 2018
Conversion to is in progress
Conversion to is failed